The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease
| Autor: | Frank L.J. Visseren, Charlotte Koopal, Jan Westerink, Britt E. Heidemann, Michiel L. Bots, Folkert W. Asselbergs |
|---|---|
| Přispěvatelé: | Cardiology |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Very low-density lipoprotein Apolipoprotein B Lipoproteins Cholesterol VLDL Lipoproteins VLDL 030204 cardiovascular system & hematology Coronary artery disease 03 medical and health sciences 0302 clinical medicine Interquartile range Internal medicine medicine Humans Prospective Studies 030212 general & internal medicine Prospective cohort study Cardiovascular Diseases/diagnosis Triglycerides Aged biology Vascular disease business.industry Middle Aged Atherosclerosis medicine.disease Cholesterol Cardiovascular Diseases Cohort biology.protein Cardiology Female lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business VLDL Mace |
| Zdroj: | International journal of cardiology, 322, 251-257. Elsevier Ireland Ltd |
| ISSN: | 0167-5273 |
| DOI: | 10.1016/j.ijcard.2020.08.030 |
| Popis: | Introduction Apolipoprotein B containing lipoproteins are atherogenic. There is evidence that with low plasma low density lipoprotein cholesterol (LDL-C) levels residual vascular risk might be caused by triglyceride rich lipoproteins such as very-low density lipoproteins (VLDL), chylomicrons and their remnants. We investigated the relationship between VLDL-cholesterol (VLDL-C) and recurrent major adverse cardiovascular events (MACE), major adverse limb events (MALE) and all-cause mortality in a cohort of patients with cardiovascular disease. Methods Prospective cohort study in 8057 patients with cardiovascular disease from the UCC-SMART study. The relation between calculated VLDL-C levels and the occurrence of MACE, MALE and all-cause mortality was analyzed with Cox regression models. Results Patients mean age was 60 ± 10 years, 74% were male, 4894 (61%) had coronary artery disease, 2445 (30%) stroke, 1425 (18%) peripheral arterial disease and 684 (8%) patients had an abdominal aorta aneurysm at baseline. A total of 1535 MACE, 571 MALE and 1792 deaths were observed during a median follow up of 8.2 years (interquartile range 4.512.2). VLDL-C was not associated with risk of MACE or all-cause mortality. In the highest quartile of VLDL-C the risk was higher for major adverse limb events (MALE) (HR 1.49; 95%CI 1.16–1.93) compared to the lowest quartile, after adjustment for confounders including LDL-C and lipid lowering medication. Conclusion In patients with clinically manifest cardiovascular disease plasma VLDL-C confers an increased risk for MALE, but not for MACE and all-cause mortality, independent of established risk factors including LDL-C and lipid-lowering medication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect